In the gastrointestinal disorders, the combination of EGFR inhibitor and gemcitabine was more toxic compared to gemcitabine alone, with the increased risk of vomiting (OR: 2.96; 95% CI: 1.42–6.15; p = 0.004; heterogeneity: I2 = 0%). This evidence concerns the gene EGFR and digestive system disorder.